Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Currently, the potential risk of atrial fibrillation associated with antihyperglycemic drug use has been a topic of considerable interest. However, it remains uncertain whether different classes of antihyperglycemic drug therapy are associated with the risk of atrial fibrillation risk. Here, we investigated the association between different classes of antihyperglycemic drugs and new-onset atrial fibrillation (NAF). A case-matched study was performed based on the National Health Insurance Program in Taiwan. Patients who had NAF were considered the NAF group and were matched in a 1:4 ratio with patients without NAF, who were assigned to the non-NAF group. Patients were matched according to sex, age, diabetes mellitus duration, index date, and Charlson Comorbidity Index score. We used multivariate logistic regression controlling for potential confounders to examine the association between different classes of antihyperglycemic drug use and the risk of NAF. Overall, we identified 2,882 cases and 11,528 matched controls for the study. After adjusting for sex, age, comorbidities, and concurrent medications, users of biguanides or thiazolidinediones were at a lower risk of developing NAF when compared with non-users (odds ratio [OR] 0.81, 95% confidence interval [CI] 0.71-0.95 and OR 0.72, 95% CI 0.63-0.83, respectively). In contrast, users of insulin were at a higher risk of developing NAF than were non-users (OR 1.19, 95% CI 1.06-1.35). Sulfonylureas, glinides, α-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were not associated with developing the risk of NAF. In conclusion, the use of biguanides or thiazolidinediones may be associated with a low risk of NAF, whereas insulin may be associated with a significant increase in the risk of NAF in patients with type 2 diabetes mellitus during long-term follow-up. Further prospective randomized studies should investigate which specific class of antihyperglycemic drug treatment for diabetes mellitus can prevent or postpone NAF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the EMPA-REG OUTCOME trial, empagliflozin, compared with placebo, reduced CV death or HF hospitalization consistently in patients with diabetes with or without AF (P int = 0.56).604”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [604]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal
Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00031.2009 · Cited by 1,273
Wu, C.-Y., Chen, Y.-J., Ho, H. J., Hsu, Y.-C., Kuo, K. N., Wu, M.-S., & Lin, J.-T. (2012) · JAMA · doi:10.1001/2012.jama.11975 · Cited by 818
Piccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N., Hernandez, A. F., Heckbert, S. R., Benjamin, E. J., & Curtis, L. H. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.962688 · Cited by 565
Huxley, R. R., Filion, K. B., Konety, S., & Alonso, A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.004 · Cited by 561
Recent advances in the molecular pathophysiology of atrial fibrillation
Wakili, R., Voigt, N., Kääb, S., Dobrev, D., & Nattel, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46315 · Cited by 545
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.540480 · Cited by 420
Conen, D. (2011) · JAMA · doi:10.1001/jama.2011.659 · Cited by 345
Diabetes mellitus, glycemic control, and risk of atrial fibrillation
Dublin, S., Glazer, N. L., Smith, N. L., Psaty, B. M., Lumley, T., Wiggins, K. L., Page, R. L., & Heckbert, S. R. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1340-y · Cited by 310
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Atrial Fibrillation and Diabetes Mellitus
Wang, A., Green, J. B., Halperin, J. L., & Piccini, J. P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.020 · Cited by 400
Batta, A., Hatwal, J., Batta, A., Verma, S., & Sharma, Y. P. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i5.229 · Cited by 122
Chen, H.-Y., Huang, J., Siao, W.-Z., & Jong, G. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01048-x · Cited by 109
Self-citationMetabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
Bode, D., Pronto, J. R. D., Schiattarella, G. G., & Voigt, N. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01038-6 · Cited by 109
“Strikingly, in a retrospective case–control study, patients treated with insulin were at higher risk of developing AF than patients who were not receiving insulin 30 .”
Metadata
- Authors
- Liou, Y.-S., Yang, F.-Y., Chen, H.-Y., & Jong, G.-P.
- Affiliations
- Taichung Veterans General Hospital (TW)
- China Medical University (TW)
- Chung Shan Medical University Hospital (TW)
- Corresponding author
- Jong, Gwo-Ping
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-08-30
- Volume
- 13
- Issue
- 8
- Pages
- e0197245
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6116917
- OpenAlex
- W2889208017
- Cited by
- 75
- References
- 38
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 20 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 1
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chung Shan Medical University Hospital (2016-012)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- new-onset atrial fibrillation, antidiabetic drugs, type 2 diabetes, biguanides, thiazolidinediones, insulin, sulfonylureas, glinides, alpha-glucosidase inhibitors, DPP-4 inhibitors
- MeSH terms
- Aged, Atrial Fibrillation, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Sulfonylurea Compounds, Taiwan, Case-Control Studies, Age of Onset, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. https://app.cochat.ai/papers/10.1371/journal.pone.0197245
- The paper
- Liou, Y.-S., Yang, F.-Y., Chen, H.-Y., & Jong, G.-P. (2018). Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. PLOS ONE. https://doi.org/10.1371/journal.pone.0197245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.